Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study

[1] Sakai F(2016)Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 17 954-976

[2] Igarashi H(1997)Prevalence of migraine in Japan: a nationwide survey Cephalalgia 17 15-22

[3] Sakai F(2021)Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients Headache 61 1102-1111

[4] Suzuki N(2021)Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study Headache 61 927-935

[5] Kim BK(2018)Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial Cephalalgia 38 1442-1454

[6] Tatsuoka Y(2017)A Controlled Trial of Erenumab for Episodic Migraine N Engl J Med 377 2123-2132

[7] Imai N(2018)Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial JAMA 319 1999-2008

[8] Ning X(2022)Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial Cephalalgia 42 108-118

[9] Ishida M(2022)Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis BMC Neurol 22 512-1217

[10] Nagano K(2021)Predictors of response to erenumab after 12 months of treatment Brain Behav 11 e2260-1208

[1] Sakai F(2016)Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 17 954-976

[2] Igarashi H(1997)Prevalence of migraine in Japan: a nationwide survey Cephalalgia 17 15-22

[3] Sakai F(2021)Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients Headache 61 1102-1111

[4] Suzuki N(2021)Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study Headache 61 927-935

[5] Kim BK(2018)Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial Cephalalgia 38 1442-1454

[6] Tatsuoka Y(2017)A Controlled Trial of Erenumab for Episodic Migraine N Engl J Med 377 2123-2132

[7] Imai N(2018)Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial JAMA 319 1999-2008

[8] Ning X(2022)Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial Cephalalgia 42 108-118

[9] Ishida M(2022)Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis BMC Neurol 22 512-1217

[10] Nagano K(2021)Predictors of response to erenumab after 12 months of treatment Brain Behav 11 e2260-1208